KCT0006806Recruiting未知
Statin therapy on prevention for composite event outcome (stroke recurrence, myocardial infarction, or all-cause death) in acute cardioembolic stroke patients with no definite indication for statin: A registry-based randomized controlled trial
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Enrollment
- 1,152
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional Study
Eligibility Criteria
- Ages
- 19(Year) to o Limit (—)
- Sex
- All
Inclusion Criteria
- •1. Patients with ischemic stroke or transient ischemic attack confirmed by neuroimaging study
- •2. 19 years old or older
- •3. known or newly-documented high-risk cardioembolic source
- •High-risk cardioembolic sources: atrial fibrillation, atrial flutter, mechanical prosthetic valve, left atrial or atrial appendage thrombus, sick sinus syndrome, left ventricular thrombus, dilated cardiomyopathy
- •4. no use of statin prior to the index stroke
- •5. no statin benefit group
- •- statin benefit groups
- •? Clinical atherosclerotic cardiovascular disease (ASCVD): Acute coronary
- •syndrome, history of myocardial infarction, stable or unstable angina or
- •coronary or other arterial revascularization, stroke transient ischemic attack, or peripheral artery disease, aortic aneurysm, all of atherosclerotic origin
- •? Age 20-75y & Low density lipoprotein-cholesterol (LDL-C) =190mg/dl
- •? Age 40-75y & Diabetes & LDL-C 70-189mg/dl
- •? Age 40-75 & no diabetes & LDL-C 70-189mg/dl & 10y ASCVD risk =7.5%
- •6. patients signed informed consent
Exclusion Criteria
- •1. abnormal liver function test (AST or ALT> 200 IU/L)
- •2. allergy or contraindication for statin
- •3. pregnancy or breast-feeding
- •4. participation to other randomized trial regarding drug for dyslipidemia
- •5. life expectancy - less than 6 months
- •6. taking prohibited medications
- •? other statin
- •? PCSK-9 inhibitor
- •? cyclosporin
- •? fenofibrate
- •? other drugs that might influence the efficacy of intervention drug
Investigators
Similar Trials
Active, not recruiting
Phase 1
Statins for treatment of liver cirrhosis. The STATLiver TrialEUCTR2019-001806-40-DKAfsnit 360, Gastroenheden182
Completed
Not Applicable
The role of high dose statins in the prevention of postoperative atrial fibrillation in patients undergoing cardiac surgeryAtrial fibrillationCirculatory SystemISRCTN41309956St. George's Hospital Charitable Foundation (UK)450
Active, not recruiting
Not Applicable
Prevention of cardiovascular events in in patients with pneumoniaPatients hospitalized with community-acquired pneumoniaEUCTR2013-002799-42-ITDipartimento di Medicina Interna e Specialità Mediche - Policlinico Umberto I - Sapienza Università di Roma
Completed
Not Applicable
Evaluation of combination therapy with Statin and Ezetimible for patients with type II diabetes.Pateients with type II diabetes combined with dyslipidemiaJPRN-UMIN000002261Department of Cardiovascular Medicine, Saga University30
Terminated
Phase 3
atural products to lower cholesterolstatin intoleranceCardiovascular - Other cardiovascular diseaseshyperlipidemiacardiovascular diseaseACTRN12618000660280Curtin University49